Color’s 30-gene test for hereditary cancer and Cynvenio’s next-generation sequencing breast cancer test are now offered as a unified solution for assessing breast cancer risk with cost-effective patient monitoring.
Read More
The task force encourages men aged 55 to 69 to make an individualized decision about prostate cancer screening with their clinician, and recommends against screening men aged 70 years and older.
Read More
The company will use the award to prepare an international clinical study to evaluate its MCM5 ELISA-based urine test for prostate cancer.
Read MoreThe highly multiplexed mixes include 15 clinically actionable fusion RNA partners.
Read More
This issue’s Product Spotlight features emerging technologies from Bio-Rad Laboratories, Exact Diagnostics, Miacom Diagnostics, and more.
Read More